Anti-proliferative effects of O-acyl-low-molecular-weight heparin derivatives on bovine pulmonary artery smooth muscle cells (Q35603850)

9 August 2017

title

Anti-proliferative effects of O-acyl-low-molecular-weight heparin derivatives on bovine pulmonary artery smooth muscle cells (English)

1 reference

9 August 2017

8

Robert J Linhardt

1 reference

9 August 2017

Hari G Garg

1

1 reference

9 August 2017

Hicham Mrabat

2

1 reference

9 August 2017

Lunyin Yu

3

1 reference

9 August 2017

Charles A Hales

4

1 reference

9 August 2017

Boyangzi Li

5

1 reference

9 August 2017

Casey N Moore

6

1 reference

9 August 2017

Fuming Zhang

7

1 reference

9 August 2017

publication date

20 July 2011

1 reference

9 August 2017

published in

Glycoconjugate Journal

1 reference

9 August 2017

volume

28

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

419-426

1 reference

Significance of the 2-O-sulfo group of L-iduronic acid residues in heparin on the growth inhibition of bovine pulmonary artery smooth muscle cells

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Increase in the growth inhibition of bovine pulmonary artery smooth muscle cells by an O-hexanoyl low-molecular-weight heparin derivative

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Heparin and heparan sulfate: structure and function

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Role of heparan sulfate in fibroblast growth factor signalling: a structural view

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Terminally alkylated heparin. 2. Potent antiproliferative agent for vascular smooth muscle cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Terminally alkylated heparin. 1. Antithrombogenic surface modifier

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Enzymatic modification of heparan sulfate on a biochip promotes its interaction with antithrombin III

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

FGFs, heparan sulfate and FGFRs: complex interactions essential for development

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Regulation of differentiation of vascular smooth muscle cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Structure and biological activity of heparin.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Antiproliferative effects of novel, nonanticoagulant heparin derivatives on vascular smooth muscle cells in vitro and in vivo

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Gradient polyacrylamide gel electrophoresis for determination of molecular weights of heparin preparations and low-molecular-weight heparin derivatives

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

New findings in pulmonary arteries of rats with hypoxia-induced pulmonary hypertension

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Influence of molecular weight, protein core and charge of native heparin fractions on pulmonary artery smooth muscle cell proliferation

12 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-011-9341-6

O-acylated heparin derivatives with low anticoagulant activity decrease proliferation and increase alpha-smooth muscle actin expression in cultured arterial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-011-9341-6

Fibroblast growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-011-9341-6

Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-011-9341-6

Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234589

Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin

25 September 2018

1 reference

12 December 2020

Impairment of hypoxic pulmonary artery remodeling by heparin in mice

1 reference

12 December 2020

Effect of heparin on vascular smooth muscle cells. I. Cell metabolism

1 reference

12 December 2020

Pharmacologic properties of an unfractionated heparin butyryl derivative with long-lasting effects

1 reference

12 December 2020

Differential effect of three commercial heparins on Na+/H+ exchange and growth of PASMC

1 reference

12 December 2020

Effect of fully sulfated glycosaminoglycans on pulmonary artery smooth muscle cell proliferation

1 reference

12 December 2020

Oral heparin prevents neointimal hyperplasia after arterial injury: inhibitory potential depends on type of vascular injury

1 reference

12 December 2020

Further evidence that periodate cleavage of heparin occurs primarily through the antithrombin binding site

1 reference

12 December 2020

Heparin antiproliferative activity on bovine pulmonary artery smooth muscle cells requires both N-acetylation and N-sulfonation

1 reference

12 December 2020

Primary pulmonary hypertension

1 reference

12 December 2020

Heparin fails to inhibit the proliferation of human vascular smooth muscle cells in the presence of human serum

1 reference

12 December 2020

Sulfation patterns in heparin and heparan sulfate: effects on the proliferation of bovine pulmonary artery smooth muscle cells

1 reference

12 December 2020

10.1007/S10719-011-9341-6

Identifiers

DOI

1 reference

release_prpiks5tzfhhfmm2ygpfc3mmfq

9 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/prpiks5tzfhhfmm2ygpfc3mmfq

24 November 2022

mapped directly with Wikidata item

PMC publication ID

3234589

1 reference

9 August 2017

1 reference